Luye Pharma Group Ltd., commonly referred to as Luye Pharma, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in China (CN). Established in 1997, the company has made significant strides in developing innovative drug delivery systems and specialty pharmaceuticals, focusing on areas such as oncology, central nervous system disorders, and cardiovascular diseases.
With a strong operational presence in Asia, Europe, and the Americas, Luye Pharma is recognised for its unique core products, including long-acting injectables and transdermal patches, which enhance patient compliance and therapeutic efficacy. The company has achieved notable milestones, including multiple product approvals and a robust pipeline of new therapies, solidifying its market position as a leader in advanced pharmaceutical solutions.
-13 vs industry average
Luye Pharma’s score of 26 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Luye Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Luye Pharma's reported carbon emissions
Luye Pharma, a pharmaceutical preparation manufacturer headquartered in China, has reported Scope 1 and Scope 2 emissions data for several years.
In 2024, Luye Pharma's total Scope 1 and Scope 2 emissions were approximately 67.7 million kg CO2e. This breaks down into roughly 10 million kg CO2e for Scope 1 and 57.6 million kg CO2e for Scope 2.
The company's emissions for previous years include:
- 2023: Approximately 76.2 million kg CO2e (Scope 1: about 10.7 million kg CO2e, Scope 2: about 65.5 million kg CO2e)
- 2022: Approximately 78.1 million kg CO2e (Scope 1: about 10.7 million kg CO2e, Scope 2: about 67.9 million kg CO2e)
- 2021: Approximately 68.5 million kg CO2e (Scope 1: about 10 million kg CO2e, Scope 2: about 58.5 million kg CO2e)
- 2020: Approximately 72.1 million kg CO2e (Scope 1: about 10.4 million kg CO2e, Scope 2: about 61.7 million kg CO2e)
- 2019: Approximately 63.2 million kg CO2e (Scope 1: about 8.5 million kg CO2e, Scope 2: about 54.7 million kg CO2e)
- 2018: Approximately 51.3 million kg CO2e (Scope 1: about 9.1 million kg CO2e, Scope 2: about 42.2 million kg CO2e)
Luye Pharma's reporting indicates that Scope 3 emissions data, specifically for purchased goods and services, is currently missing. The company has not publicly disclosed specific reduction targets or climate commitments, such as through SBTi or Climate Pledge initiatives, based on the provided information. However, the company's reporting includes intensity metrics for greenhouse gas emissions per unit of revenue and waste production.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Luye Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Luye Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Luye Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project